We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Molecular Assay Detects Pathogenic Fungi

By LabMedica International staff writers
Posted on 04 Oct 2011
A real-time polymerase chain reaction (PCR) assay detects and differentiates dimorphic fungi from culture isolates and directly from clinical specimens. More...


Primers and fluorescence resonance energy transfer-hybridization probes were designed to identify specific genes of Blastomyces dermatitidis and Histoplasma capsulatum, two pathogenic fungi that may cause severe mycoses.

Scientists at the Mayo Clinic (Rochester, MN, USA) collected over a 12-month period, 797 clinical specimens from patients with suspected fungal infection that were analyzed immediately. Primers and fluorescence resonance energy transfer (FRET) hybridization probes were designed to target a 174-base pair (bp) region of the dimorphism-regulating histidine kinase (DRK-1) gene of B. dermatitidis and a 192-bp region of the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene of H. capsulatum. Respiratory specimens, such as bronchial washings, bronchoalveolar fluid and pleural fluid, were also cultured.

The real-time PCR assay was developed on the LightCycler 2.0 instrument (Roche Applied Sciences, Indianapolis, IN, USA). The analytical sensitivity was determined to be 100 copies/µL for B. dermatitidis and H. capsulatum. From culture isolates, the assay demonstrated 100% specificity and 100% sensitivity for B. dermatitidis and 100% specificity and 94% sensitivity for H. capsulatum. Direct detection from the 797 clinical specimens demonstrated specificities and sensitivities of 99% and 86% for B. dermatitidis and 100% and 73% for H. capsulatum compared with the results for culture. There was no cross reactivity with other pathogenic fungi and the assay could detect and differentiate B. dermatitidis and H. capsulatum directly from clinical specimens within about four hours from specimen receipt.

Although microbiologic culture is a standard method for detecting these pathogens, their recovery may require days to weeks, and the manipulation of cultures presents a significant safety hazard to laboratory personnel. The authors concluded that the real-time PCR assay offers a rapid, sensitive, and specific method for the detection and differentiation of B. dermatitidis and H. capsulatum from culture isolates and clinical specimens. An additional advantage of the real-time PCR assay is increased safety for laboratory personnel by reducing the need to manipulate cultures of specimens that are positive by the PCR assay. The study was published in September 2011, in the Journal of Clinical Microbiology.

Related Links:
Mayo Clinic
Roche Applied Sciences



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Blood Ammonia Test Analyzer
DRI-CHEM NX10N
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.